Payment overview · 2025
General Payments
$973.17
36 reported records · 20 companies
Healthcare provider profile · identity verified
Shanti Thomas, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Medical Oncology · BROWNSTOWN TWP, MI · NPI 1083707111
Verified facts
What the public records show
CMS Open Payments records show Shanti Thomas, M.D. received $973.17 in general payments during 2025 across 36 reported records.
Novartis Pharmaceuticals Corporation accounted for 14.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ibrance, Jakafi.
BeOne Medicines USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRUKINSA as an associated drug or biological on 10251 records involving 4941 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Brukinsa by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Venclexta as an associated drug or biological on 2896 records involving 2018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Venclexta by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Erleada by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Imbruvica by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PIQRAY as an associated drug or biological on 36 records involving 4 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Piqray by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ibrance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $135.85 | 14.0% | 6 | 2025 |
| Aveo Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $114.21 | 11.7% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $93.95 | 9.7% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $76.45 | 7.9% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $65.96 | 6.8% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $58.92 | 6.0% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $53.90 | 5.5% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $47.19 | 4.8% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $43.22 | 4.4% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $42.42 | 4.4% | 2 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $33.55 | 3.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $26.78 | 2.8% | 1 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $25.13 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $24.64 | 2.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $24.15 | 2.5% | 1 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $23.17 | 2.4% | 1 | 2025 |
| Genmab U.S., Inc. | Unresolved — no canonical attribution shown | $23.13 | 2.4% | 1 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $21.41 | 2.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.10 | 2.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.04 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $754.32 | 33 |
| Education | $218.85 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $115.82 | 5 | 2025 |
Source payment records
|
|||||
| FOTIVDA Normalized: fotivda |
Drug | Aveo Pharmaceuticals, Inc. | $114.21 | 2 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $58.92 | 3 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | Sumitomo Pharma America, Inc. | $53.90 | 1 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $47.19 | 2 | 2025 |
Source payment records
|
|||||
| Polivy Normalized: polivy |
Biological | Genentech USA, Inc. | $46.44 | 2 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $43.22 | 2 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $43.08 | 2 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $36.62 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $33.55 | 2 | 2025 |
Source payment records
|
|||||
| Tecentriq Normalized: tecentriq |
Biological | Genentech USA, Inc. | $30.01 | 1 | 2025 |
Source payment records
|
|||||
| ALUNBRIG Normalized: alunbrig |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $28.95 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $26.78 | 1 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological | Merck Sharp & Dohme LLC | $26.78 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Drug | Blueprint Medicines Corporation | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | PFIZER INC. | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| Doptelet Normalized: doptelet |
Drug | SOBI, INC | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| Epkinly Normalized: epkinly |
Drug | Genmab U.S., Inc. | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| IBRANCE ibrance |
2025 | Ibrance | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| BeOne Medicines USA, Inc. Exact reporting entity; no affiliate inference |
2025 | BRUKINSA open payments reported associated product |
CMS Open Payments — General Payments 10251 supporting records · 4941 recipient NPIs · example record 1202883638 |
Brukinsa · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Venclexta open payments reported associated product |
CMS Open Payments — General Payments 2896 supporting records · 2018 recipient NPIs · example record 1211488584 |
Venclexta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PIQRAY open payments reported associated product |
CMS Open Payments — General Payments 36 supporting records · 4 recipient NPIs · example record 1200336082 |
Piqray · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Anastrozole | Anastrozole | 463 | 120 |
| Alendronate Sodium | Alendronate Sodium | 142 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 134 | 33 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 90 | 46 |
| Acyclovir | Acyclovir | 77 | 15 |
| Omeprazole | Omeprazole | 75 | 24 |
| Imatinib Mesylate | Imatinib Mesylate | 74 | suppressed |
| Gabapentin | Gabapentin | 69 | 18 |
| Tamoxifen Citrate | Tamoxifen Citrate | 63 | 19 |
| Potassium Chloride | Potassium Chloride | 61 | 20 |
| Hydroxyurea | Hydroxyurea | 58 | 18 |
| Eliquis | Apixaban | 53 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | suppressed |
| Dexamethasone | Dexamethasone | 40 | 16 |
| Exemestane | Exemestane | 40 | 15 |
| Alprazolam | Alprazolam | 39 | 12 |
| Letrozole | Letrozole | 35 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 34 | 12 |
| Allopurinol | Allopurinol | 33 | 12 |
| Brukinsa | Zanubrutinib | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 31 | 11 |
| Ondansetron Odt | Ondansetron | 29 | 20 |
| Imbruvica | Ibrutinib | 27 | suppressed |
| Lenalidomide | Lenalidomide | 27 | suppressed |
| Anagrelide Hcl | Anagrelide Hcl | 26 | suppressed |
| Erleada | Apalutamide | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 12 |
| Ibrance | Palbociclib | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Revlimid | Lenalidomide | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 15 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 15 | 14 |
| Jakafi | Ruxolitinib Phosphate | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Posaconazole | Posaconazole | 14 | suppressed |
| Lumakras | Sotorasib | 13 | suppressed |
| Piqray | Alpelisib | 13 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 13 | suppressed |
| Gilotrif | Afatinib Dimaleate | 12 | suppressed |
| Pomalyst | Pomalidomide | 12 | suppressed |
| Venclexta | Venetoclax | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $973.17 · 36 records | Novartis Pharmaceuticals Corporation | ALUNBRIG, AYVAKIT, CARVYKTI, Doptelet, ENHERTU, Epkinly, FOTIVDA, FRUZAQLA, IBRANCE, JAKAFI, KEYTRUDA, KISQALI, LYNPARZA, Lenvima, OJJAARA, ORGOVYX, Orserdu, PLUVICTO, Polivy, TEVIMBRA, TUKYSA, Tecentriq, Trodelvy, Vanflyta | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ibrance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with BeOne Medicines USA, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error